Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push

Benzinga_recent_news03:17

Dr. Reddy’s Laboratories Limited (NYSE:RDY) on Friday launched its generic Semaglutide Injection in Canada. This move is significant as it positions Dr. Reddy’s among the first companies to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636067665?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,dpr=2,format=auto,quality=85/files/images/story/2026/05/16/Stuttgart--Germany---05-30-2021-Person-H.jpeg","is_english":true,"pubTime":"2026-05-17 03:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636067665","market":"hk","top_or_hot":-1,"title":"Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push","media":"Benzinga_recent_news","content":"<div>\n<p>Dr. Reddy’s Laboratories Limited  (NYSE:RDY) on Friday launched its generic Semaglutide Injection in Canada. \nThis move is significant as it positions Dr. Reddy’s among the first companies to ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/05/52623000/dr-reddys-launches-generic-semaglutide-in-canada-expands-glp-1-push\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-17 03:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/26/05/52623000/dr-reddys-launches-generic-semaglutide-in-canada-expands-glp-1-push><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dr. Reddy’s Laboratories Limited  (NYSE:RDY) on Friday launched its generic Semaglutide Injection in Canada. \nThis move is significant as it positions Dr. Reddy’s among the first companies to ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/26/05/52623000/dr-reddys-launches-generic-semaglutide-in-canada-expands-glp-1-push\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4596","symbol_name":"哈里斯概念","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/26/05/52623000/dr-reddys-launches-generic-semaglutide-in-canada-expands-glp-1-push","article_id":"2636067665","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,dpr=2,format=auto,quality=85/files/images/story/2026/05/16/Stuttgart--Germany---05-30-2021-Person-H.jpeg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/26/05/52623000/dr-reddys-launches-generic-semaglutide-in-canada-expands-glp-1-push","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636067665","pubTimestamp":1778959020,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Dr. Reddy's launched generic Semaglutide Injection in Canada, expanding its GLP-1 portfolio and strengthening its affordable diabetes treatment presence.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4596":"哈里斯概念","BK4144":"石油与天然气的储存和运输","RDY":"如瑞迪博士","BK4007":"制药","RSI":"Rush Street Interactive, Inc.","SMA":"Smartstop Self Storage REIT Inc","BK4590":"PTP","BK4217":"自存仓储房地产信托","BK4150":"赌场与赌博","BK4523":"印度概念","BK4557":"大麻股","BK4532":"文艺复兴科技持仓","GLP":"Global Partners Lp","LU0348744763.USD":"ALLIANZ ASIA PACIFIC INCOME \"A\" (USD) INC"},"translate_title":"Dr.Reddy's在加拿大推出仿制药索马鲁肽，扩大GLP-1推广范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSI":1,"RDY":1,"SMA":1,"GLP":1.5},"content_text":"Dr. Reddy’s Laboratories Limited  (NYSE:RDY) on Friday launched its generic Semaglutide Injection in Canada. \nThis move is significant as it positions Dr. Reddy’s among the first companies to introduce this generic product in the Canadian market, which is a notable expansion for the company after receiving approval from Health Canada.\nDr. Reddy’s has launched its generic Semaglutide Injection, indicated for the treatment of type 2 diabetes, shortly after receiving market authorization on April 28, 2026. This launch underscores the company’s commitment to enhancing patient access to affordable medications in Canada, a market where it aims to establish a strong foothold.\nDespite the positive news for Dr. Reddy’s, the broader market faced challenges, with major indices like the Nasdaq down 1.90% and the S&P 500 down 1.45%. This mixed market backdrop suggests that while Dr. Reddy’s is making strides in product offerings, it is navigating a generally bearish market environment.\nFrom a technical perspective, Dr. Reddy’s shares are currently trading 1.8% above the 20-day simple moving average (SMA) of $13.37, indicating a short-term bullish sentiment. However, the stock is 0.9% below the 100-day SMA of $13.74 and 2.3% below the 200-day SMA of $13.93, which suggests potential resistance at these levels.\nThe Relative Strength Index (RSI) currently sits at 53.44, indicating a neutral momentum phase, suggesting that the stock is neither overbought nor oversold. This neutral reading implies that there may be room for further price movement in either direction, depending on market conditions and upcoming catalysts.\nKey Resistance: $14.50 — a nearby level where rebounds can stall. \nKey Support: $13.50 — a nearby level where buyers previously stepped in.\nDr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries.\nBeyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables, which make up 25% of its North America sales. The recent launch of its generic Semaglutide Injection in Canada highlights its strategy to expand access to GLP-1 therapies, reinforcing its commitment to providing affordable healthcare solutions.\nDr. Reddy’s Laboratories Limited is slated to provide its next financial update on July 22, 2026 (estimated).\nAnalyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $13.33. Recent analyst moves include:\nBelow is the Benzinga Edge scorecard for Dr. Reddy’s Laboratories Limited American Depositary Shares, highlighting its strengths and weaknesses compared to the broader market:\nThe Verdict: Dr. Reddy’s Laboratories Limited American Depositary Shares’s Benzinga Edge signal reveals a mixed profile, with strong value and growth rankings but weak momentum. This suggests that while the company is well-positioned in terms of fundamentals, it may face challenges in maintaining upward price movement in the current market environment.\nRDY Stock Price Activity: Dr Reddy’s Laboratories shares were up 0.22% at $13.64 on Friday, according to Benzinga Pro data.\nPhoto by T. Schneider via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636067665","isCrawlerRequest":true}